The purpose of the study is to evaluate the effect of psilocybin on symptoms of the disorder. Participants receive the medication under supervision, attend several therapy sessions over a period of weeks, and return for follow‑up visits to track any changes. The trial follows a randomised, triple‑blind design, meaning participants are assigned by chance and neither the participants, the clinicians, nor the data analysts know who receives the active medication or the active‑placebo, ensuring unbiased results.

The purpose is to compare the safety and effectiveness of Surovatamig plus rituximab with the standard chemotherapy plus rituximab in people who have not been treated for Follicular Lymphoma. The study begins with a short safety phase to find a suitable dose, followed by a larger phase where participants receive treatment cycles over several months. Throughout the trial, regular doctor visits, blood tests and imaging scans are performed to watch for side effects and to see how the disease responds.

Participants are randomly assigned to receive either the new combination or the standard regimen; the new drugs are given by IV infusion on scheduled days while the oral pills are taken at home. The standard‑of‑care arm receives the physician‑chosen drugs (such as elotuzumab, carfilzomib or daratumumab) using the usual dosing routes. Throughout the study, blood work, imaging and a bone‑marrow test reviewed by an independent review committee (IRC) using criteria from the International Myeloma Working Group (IMWG) are performed to follow the disease. Additional outcomes include measures such as overall survival (OS), very good partial response (VGPR), overall response rate (ORR), time to first response (TTR), time to deepest response (TTBR) and duration of response (DOR). Safety is checked with standard grading systems from the NCI (CTCAE) and the ASTCT for side‑effects such as cytokine release syndrome (CRS), immune‑cell neurotoxicity (ICANS) and severe inflammation syndromes (HLH, IEC-HS). Patients also complete quality‑of‑life questionnaires from the EORTC (QLQ-MY20, QLQ-C30) and the FACTG tool, and report symptoms using the PRO-CTCAE system during regular visits until the disease progresses or the study ends.

Participants may receive one of several study medicines: an oral tablet called ibrutinib, an oral capsule named zanubrutinib, an intravenous infusion of linvoseltamab, a subcutaneous injection (under the skin) of elranatamab, a subcutaneous injection of teclistamab, or a subcutaneous injection of talquetamab. Oral medicines are taken by mouth, while the infusion is given through a vein and the injections are placed just under the skin. Each medication is given at a specific dose that is determined by the study plan.

People are randomly assigned to receive one of the medicines and are followed for a period of time with regular clinic visits, blood tests, and health questionnaires. Throughout the study, researchers track how long participants live (called overall survival) and other health outcomes such as disease progression and quality of life, while also monitoring for any side effects.

The purpose of the study is to see whether oral semaglutide can help slow worsening of memory, thinking, and daily function in people with early Alzheimer’s disease, and to check its safety. The study is randomised, which means the treatment is assigned by chance, and double-blind, which means neither the participants nor the study team knows who receives semaglutide or placebo during the study. Treatment is taken by mouth over a long period, and the study follows changes over time.

Participants take the study tablets regularly and are seen at planned visits during the trial. These visits are used to monitor health, review how the person is doing, and record any changes in memory, daily activities, or side effects. The study compares how people do over time in the semaglutide and placebo groups.

The standard treatment in this study includes bevacizumab, oxaliplatin, fluorouracil, and calcium folinate. INCA33890 is given by vein, and the other medicines are also given as injections or infusions into a vein. People in the study are assigned by chance to one of two groups: one group receives INCA33890 with the standard treatment, and the other group receives placebo with the standard treatment. The study is blinded, which means the treatment group is not known to the people taking part or to the study team during the study.

After treatment starts, the study team follows how the cancer responds and how long the treatment helps keep the disease under control. The study also looks at how long people live and at side effects, which are unwanted health problems caused by a treatment.

The study is planned in two groups, and neither the participants nor the study team will know which treatment is given. After starting treatment, the medicine is taken for a period of time and then the study looks at changes in urine protein and kidney function over about 20 weeks. The study is designed to compare BI 764198 with placebo across the different kidney disease groups.

During the trial, participants are assigned to receive either AZD0292 or a placebo. The study is double-blind, meaning that neither the participants nor the researchers know which treatment is being administered until the study is finished. The research will monitor how the medication moves through the body, a process known as pharmacokinetics, and track any pulmonary exacerbations, which are sudden increases in symptoms like coughing or shortness of breath. Participants will be monitored over a period of time to observe how the treatment affects the frequency of these lung symptom flare-ups.

The purpose of the study is to determine if BI 764198 is more effective than a placebo at reducing the amount of protein leaked into the urine. During the study, participants will take either the active medication or a placebo in the form of an oral film-coated tablet. The treatment period lasts for 104 weeks, and the process is double-blind, meaning neither the participants nor the researchers know which treatment is being administered during the trial.

Participants will be assigned to receive either olpasiran or a placebo through a subcutaneous injection, which means the medication is delivered into the fatty tissue just under the skin. During the study, researchers will monitor for various health events such as ischemic stroke, which is a blockage of blood flow to the brain, and cardiovascular death. The study will also track changes in the levels of lipoprotein (a) in the blood over time to see how the treatment affects this substance.

The purpose of the study is to evaluate how well GSK3862995B works compared with placebo in people with bronchiectasis. The study will look at whether the medication can reduce the number of times patients experience flare-ups of their condition over time. The study will also examine the safety of the medication, how the body’s immune system responds to it, and how the medication moves through and is processed by the body.

During this study, participants will receive repeated doses of either GSK3862995B or placebo over a period of time. The study is designed so that neither the participants nor the doctors will know who is receiving the actual medication and who is receiving the placebo until the study is completed. Throughout the study, doctors will monitor how often participants experience flare-ups of their bronchiectasis, how long it takes before the first flare-up occurs, and how many severe flare-ups happen. The study is expected to continue until late 2027.

The purpose of this study is to see how well these medicine combinations work at shrinking or stopping the growth of the cancer, and to check how safe they are for people to take. The study will also look at which dose levels work best when the medicines are used together compared to using tuvusertib alone. The study is divided into two parts. In the first part, called Part A, people will receive either tuvusertib combined with niraparib or tuvusertib combined with lartesertib. The results from Part A will help decide which combination works better and should be studied further. In the second part, called Part B, people will receive the best combination chosen from Part A at two different dose levels, or they will receive tuvusertib by itself. This will help compare how well the combination works compared to tuvusertib alone and will help determine the best dose to use in future treatments.

During the study, people will take their assigned medicines and will have regular check-ups to see how the cancer is responding to treatment and to watch for any side effects. These check-ups will include scans to measure the size of the cancer and blood tests to check overall health. The treatment can continue for up to 42 months as long as the cancer does not get worse and the medicine is not causing serious problems. The study will measure how many people have their cancer shrink, how long the cancer stays under control, how long people live without the cancer getting worse, and how long people live overall. The study will also carefully track any unwanted effects or health problems that occur during treatment.

The purpose of this study is to evaluate the long-term effect of tozorakimab in reducing severe flare-ups of the lung disease in people who used to smoke. The study will also look at how safe the medication is when used over a longer period of time. This is an extension study, which means it is designed for people who have already participated in earlier studies of the same medication and completed their treatment without stopping early.

Participants who join this study will continue receiving the same type of treatment they were on in the previous study for up to 52 weeks. They will attend regular clinic visits where doctors will check their lung function, ask about any breathing problems or flare-ups, and monitor for any side effects. The study will track how often participants experience severe flare-ups that require emergency room visits or hospital stays, and will measure how long it takes before these serious episodes occur. Blood samples may be collected to measure the amount of medication in the body and to check how the immune system responds to the treatment.

The purpose of this study is to measure how well this treatment combination works over a three-year period and to examine its safety in children, adolescents, and young adults with these types of leukemia. The treatment approach uses a modified chemotherapy plan that includes three cycles of blinatumomab without traditional consolidation chemotherapy, combined with continuous use of the targeted drugs. The study will track various side effects including infections, mouth sores, nerve problems, cytokine release syndrome which is a reaction from the immune system, low levels of protective antibodies in the blood, treatment delays, and deaths related to treatment.

During the study, patients will receive a combination of standard chemotherapy drugs including vincristine, steroids, and pegaspargase or calaspargase pegol, with or without an anthracycline drug. The treatment plan is designed to work differently for the two types of leukemia, with patients having already started some initial therapy before joining the study. The study will follow patients to see how many remain free from disease events over three years and will also track overall survival rates and how the treatment works based on the specific genetic changes present in each patient’s leukemia.

The purpose of this study is to find out if zongertinib works better than standard of care treatment in preventing the cancer from coming back after surgery. The study will measure how long patients live without their cancer returning, which is called disease-free survival. The study will also look at how long patients live overall and will check for any serious side effects from the treatments. Patients in this study will be randomly assigned to receive either zongertinib or one of the standard of care treatments, or they may be observed without additional treatment after surgery.

During the study, patients will be monitored regularly to check if the cancer comes back and to watch for any side effects from the treatment. The treatment with zongertinib can last up to 36 months, while the standard of care treatments can last up to 12 months. Patients will need to have their cancer tissue tested to confirm that it has the specific HER2 mutations required for the study. The study will follow patients for several years to gather information about whether the treatment helps keep the cancer from returning and to understand the safety of the medications being tested.

The purpose of this study is to see whether Tozorakimab can reduce the number of times COPD symptoms suddenly get worse, which are called exacerbations. These exacerbations are episodes when breathing problems become more severe than usual and may require additional treatment or even hospitalization. The study will compare two different amounts of Tozorakimab given as an injection under the skin to placebo, which will be added to the standard medications that participants are already taking for their COPD.

The study will last for about 52 weeks. During this time, participants will receive regular injections of either Tozorakimab or placebo, and doctors will monitor how often their COPD symptoms worsen and how severe these episodes are. The study focuses on people who have had at least two moderate episodes or one severe episode of worsening COPD symptoms in the past year, who are former smokers, and who continue to have symptoms despite using their regular COPD medications.

The main purpose of this study is to compare how long people live when treated with the investigational medicine compared to docetaxel. The study will look at this in all people whose tumors have PD-L1 levels of at least one percent, and also specifically in those whose tumors have PD-L1 levels of fifty percent or higher. People taking part will be randomly assigned to receive either the investigational medicine or docetaxel. The study will also look at other things like how well the tumors respond to treatment, how long any response lasts, and what side effects occur with each treatment.

During the study, participants will receive their assigned treatment for up to sixty months. Those receiving the investigational medicine will get it at a dose based on their body weight, while those receiving docetaxel will get it at a dose based on their body surface area. The study team will regularly check how the cancer is responding to treatment and monitor for any side effects. Participants will also be asked about their quality of life and any symptoms they are experiencing. Blood samples will be taken from those receiving the investigational medicine to measure drug levels in the body and to check for immune responses to the medicine. Tumor tissue samples will also be collected for testing to help understand how the treatments work.

The study will include adults between 40 and 80 years old who have moderate to severe lung disease with frequent flare-ups, meaning they have had at least two moderate flare-ups or one severe flare-up in the past year. Participants need to have higher levels of certain white blood cells called eosinophils in their blood. They should already be using three types of inhaled medications for their lung condition, including an inhaled steroid, for at least six months before joining the study. The study will look at how often flare-ups happen during treatment and will measure this over time.

During the study, participants will receive injections of either the study medication or placebo for up to 104 weeks. The study will measure how many flare-ups occur, how long it takes until the first flare-up happens, and how the disease affects daily life and breathing symptoms. Doctors will also track how many flare-ups require emergency room visits or hospital stays. Throughout the study, participants will continue taking their regular inhaled medications as prescribed by their doctor.

The purpose of the study is to see if ziltivekimab works better than placebo in reducing the risk of serious heart-related problems in people who have both cardiovascular disease and kidney disease along with signs of inflammation in their body. The main focus is on preventing major cardiovascular events, which include death from heart-related causes, non-fatal heart attack, and non-fatal stroke. A heart attack occurs when blood flow to part of the heart muscle is blocked, while a stroke happens when blood flow to part of the brain is interrupted.

During the study, participants will receive either ziltivekimab or placebo through regular injections while continuing their standard medical treatment. The study will track various health outcomes over time, including heart attacks, strokes, heart-related deaths, hospital admissions for heart problems, and changes in kidney function. Researchers will also monitor changes in inflammation markers in the blood, heart function measurements, and overall health status. The study will measure how the kidneys are working by looking at blood test results that show the filtering ability of the kidneys and the amount of protein in the urine, which can indicate kidney damage.

The purpose of this study is to find out if ziltivekimab works better than placebo in reducing the risk of death from heart and blood vessel problems and preventing heart failure events such as hospital stays or urgent visits for worsening heart failure. The study will also look at other health outcomes including the combined risk of death from heart problems, heart attacks, and strokes, as well as how the treatment affects kidney function, quality of life, and inflammation levels in the body. Quality of life will be measured using questionnaires that ask about symptoms and daily activities.

During the study, participants will receive monthly injections for up to 48 months. The study will track various health events including hospitalizations for heart failure, deaths, heart attacks, strokes, and changes in heart and kidney function. Blood tests will be done to measure inflammation markers like hs-CRP and heart stress markers like NT-proBNP. Heart function will be checked using echocardiography, which is an ultrasound test that creates pictures of the heart. The study will continue until enough information has been collected to determine whether ziltivekimab is effective in helping people with this type of heart failure and inflammation.

The medications being studied include clopidogrel (a blood-thinning medication), acetylsalicylic acid (also known as aspirin), and two types of cholesterol-lowering medications called atorvastatin and rosuvastatin. The purpose is to determine if these treatments, along with managing other health risk factors, can reduce the risk of serious heart and brain problems over a three-year period.

During the study, participants will take their assigned medications daily and undergo various health assessments. These will include MRI scans of the brain to check for changes, tests of memory and thinking abilities, and evaluations of daily functioning and quality of life. The study will track any heart problems, strokes, or bleeding issues that occur during the treatment period.

The purpose of this research is to determine how effective the combination of glofitamab and pirtobrutinib is in treating patients with Mantle Cell Lymphoma, both in those who have previously received treatment and in those who have never been treated before. The study includes two groups of patients: those whose disease has returned or worsened after previous treatments, and elderly patients who have not yet received any treatment for their condition.

During the study, patients will receive treatment for up to 36 months. The treatment involves regular doses of medication according to a specific schedule. Patients will be monitored throughout the study period to assess how well the treatment is working and to check for any side effects. The study team will track whether the cancer improves, stays the same, or gets worse over time.

The main purpose of this research is to determine if AZD6793 can reduce how often COPD symptoms get significantly worse (known as exacerbations) compared to placebo. The study will involve different groups of participants who will receive either different doses of AZD6793 or placebo tablets.

The treatment period will last 24 weeks, during which participants will take their assigned medication while continuing their regular breathing medications. Throughout the study, doctors will monitor participants’ breathing ability, symptoms, quality of life, and overall health. They will also check how the body handles the medication and watch for any potential side effects.

Multiple Myeloma is a type of blood cancer that affects plasma cells, which are special white blood cells that help fight infections. The study aims to determine which treatment combination is more effective at eliminating cancer cells to a level that cannot be detected by very sensitive testing methods.

The medications used in this study are given in different ways. Lenalidomide is taken by mouth in capsule form, while Daratumumab and Linvoseltamab are given through an infusion into a vein. Dexamethasone can be given either as tablets by mouth or as an injection. The treatment continues for several weeks, and patients will need regular visits to the hospital for monitoring and receiving their medications.

The study will test if taking dapagliflozin while receiving standard lymphoma treatment can help prevent heart-related side effects. Participants will receive either dapagliflozin or placebo tablets for 6 months while undergoing their regular cancer treatment. The medication or placebo will be taken by mouth once daily.

During the study, doctors will monitor heart function using various tests to measure how well the heart is working. These tests include examining heart muscle movement, blood flow patterns, and checking certain substances in the blood that can indicate heart health. The study will also track any heart-related symptoms that participants may experience during their treatment.

The purpose of this research is to determine if AZD0780 can reduce the risk of serious cardiovascular events such as heart attacks, strokes, and problems with blood flow to the legs in people with cardiovascular disease. The medication will be tested in addition to patients’ regular cholesterol-lowering treatments.

During the study, participants will receive either AZD0780 or a placebo for up to 54 months. The study team will monitor participants for any cardiovascular events, including heart-related death, heart attacks, strokes, severe leg circulation problems, and emergency procedures to restore blood flow. Throughout the study, participants will continue their usual heart medications, including their regular cholesterol-lowering treatments.

The purpose of this research is to evaluate how well CSL787 works in preventing flare-ups of the disease and to determine the most effective dose. The medication will be given through a nebulizer, which is a device that turns liquid medicine into a fine mist that can be inhaled into the lungs. The study will last for up to 12 months.

During the study, participants will be randomly assigned to receive either different doses of CSL787 or a placebo through the nebulizer. The study will monitor how long it takes before participants experience their first disease flare-up and will also track other aspects of their lung health and overall well-being. This is a double-blind study, which means neither the participants nor the doctors conducting the study will know who is receiving which treatment.

The study aims to determine which treatment combination is more effective at preventing the disease from getting worse. Patients will receive either tablets of sonrotoclax or venetoclax to take by mouth, along with infusions of obinutuzumab or rituximab given through a vein. The medications will be given over several months according to a specific schedule.

Throughout the study, doctors will monitor how well the treatments work by performing various tests and examining patients regularly. They will check for the presence of cancer cells in the blood, measure how long patients live without their disease getting worse, and track any side effects that may occur. The study is expected to continue until the end of 2031.

The purpose of this research is to determine if using these two medications together is more effective than using bevacizumab by itself in treating ovarian cancer. The study specifically looks at patients who have recently been diagnosed with advanced stages of the disease. Both medications are types of targeted therapy – bevacizumab works by affecting blood vessel growth in tumors, while trastuzumab deruxtecan is an antibody-drug conjugate that specifically targets cancer cells expressing the HER2 protein.

During the study, patients will receive treatment for up to 24 months. The medications will be given through regular infusions at specified intervals. Throughout the treatment period, doctors will monitor patients’ responses to the therapy and track any changes in their condition. This research is particularly focused on patients whose cancer shows specific levels of a protein called HER2 on their tumor cells.

The medication is given as a solution for injection under the skin (subcutaneous use). During the study, participants will receive either maridebart cafraglutide or placebo. The study will track important heart-related events that may occur, such as heart attacks, strokes, and the need for heart procedures.

The research team will monitor participants’ health throughout the study, focusing particularly on heart and blood vessel-related events. The study will look at whether the medication can help prevent serious heart problems and improve survival rates in people who have both cardiovascular disease and weight issues.

The treatment involves taking these medications in cycles. Some participants will receive bleximenib along with venetoclax and azacitidine, while others will receive venetoclax and azacitidine with a placebo. This is a double-blind study, which means neither the participants nor the researchers will know which treatment group a participant is in until the study is completed.

The study will monitor how participants respond to treatment by tracking various health indicators and will assess whether the addition of bleximenib improves complete remission (when there are no detectable cancer cells) and overall survival in patients with this type of leukemia.

The study will test whether a medication called vicadrostat (BI 690517) when used in combination with another medication called empagliflozin is better than empagliflozin alone (with placebo) for treating heart failure. The purpose of the study is to determine if this combination therapy can reduce the occurrence of cardiovascular death, hospitalizations for heart failure, or urgent heart failure visits.

Participants in this study will be randomly assigned to receive either the combination of vicadrostat and empagliflozin or empagliflozin with placebo. The study will track outcomes such as cardiovascular events and measure heart failure symptoms using a questionnaire. This is a double-blind study, which means neither the participants nor the researchers will know which treatment each participant is receiving during the study.

The purpose of the study is to compare these treatments to see which is more effective in maintaining the health of participants with advanced or recurrent endometrial cancer. Participants will receive either the combination of sacituzumab tirumotecan and pembrolizumab or pembrolizumab alone. The study will monitor the participants’ health over time to assess the progression of the disease and overall survival rates.

Throughout the study, participants will be regularly evaluated to track their response to the treatment. This includes monitoring for any side effects and changes in their quality of life. The study aims to provide valuable information on the best treatment approach for individuals with this type of endometrial cancer.

The purpose of the study is to see if the combination of Sigvotatug vedotin and pembrolizumab is better at treating NSCLC compared to using pembrolizumab alone. Participants in the study will be randomly assigned to receive either the combination treatment or pembrolizumab by itself. The study will monitor how long patients live and how long they remain free from cancer progression. The trial will also look at the safety of the treatments and any side effects that may occur.

Participants will receive the treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will take place over several months, with regular check-ups to monitor the participants’ health and the effectiveness of the treatment. The trial aims to provide valuable information that could improve treatment options for people with advanced non-small cell lung cancer.

The purpose of the study is to evaluate how well these vaccines work in producing an immune response and how safe they are for the participants. The study will involve receiving one of the vaccines through an injection. Participants will be monitored for their immune response to the vaccine strains, which are specific types of the flu virus, and for any side effects. The study will last for about a year, with the main focus on the immune response measured at 29 days after vaccination.

Participants will include healthy individuals or those with stable health conditions that increase their risk of complications from the flu. The study aims to ensure that the high-dose vaccine is as effective and safe as the other vaccines. The vaccines are administered using a pre-filled syringe, which is a single-use device. The study will help determine the best vaccine option for older adults to protect them against the flu.

The research involves three different age groups: children aged 2 to 9 years, toddlers aged 12 to 15 months, and infants aged 2 months. Some participants will receive the new MenPenta vaccine alone, while others will receive it along with standard childhood vaccines. The study will monitor how well the immune system responds to the vaccine and track any side effects that may occur.

During the study, participants will receive multiple doses of vaccines through intramuscular injection. Blood samples will be taken to measure the body’s immune response to the vaccines. The researchers will carefully monitor all participants for immediate reactions after vaccination and continue to track their health throughout the study period. Other routine vaccines that may be given during the study include Prevenar 13 (for protection against pneumococcal disease), Hexyon (a combination vaccine that protects against six different diseases), and RotaTeq (for protection against rotavirus).

The purpose of the study is to evaluate the safety and effectiveness of these treatments in preventing symptoms of COVID-19. Participants will receive either Sipavibart, EVUSHELD, or a placebo. The study will monitor participants over a period of time to see if they develop symptoms of COVID-19 and to assess any side effects from the treatments. The study will also look at how well the treatments work against different variants of the virus.

Participants in the study will be monitored for any side effects and the occurrence of COVID-19 symptoms. The study will also measure the levels of the treatments in the body over time. This research aims to provide valuable information on how these treatments can help protect people with immune system challenges from COVID-19.

The purpose of the study is to determine how effective the intertransverse process block is in managing pain. Participants in the study will receive either a single or multiple injections of the medications. The study will observe how well the block works by measuring the number of areas on the body that become numb, as well as other factors like changes in skin temperature and blood pressure. Participants will also be asked about their satisfaction with the pain relief they experience.

The study is designed to be a crossover trial, which means that participants will receive both types of injections at different times. This allows researchers to compare the effects of single versus multiple injections in the same individuals. The trial is conducted with healthy volunteers to ensure the safety and effectiveness of the procedure before it is used more widely in patients undergoing breast cancer surgery.

The purpose of this research is to determine how well ibuzatrelvir works compared to placebo in treating people with COVID-19 who are at high risk of their condition becoming worse. The study will include both adults and adolescents who weigh at least 40 kilograms (about 88 pounds) and who cannot or choose not to take other available COVID-19 treatments.

During the study, participants will take either ibuzatrelvir tablets or placebo tablets. The researchers will monitor participants for 28 days to see if they need emergency care, require oxygen support, need additional treatments, are hospitalized, or experience other health issues. They will also track how quickly symptoms improve and check for any lasting effects of COVID-19 for up to 24 weeks after treatment begins.

Participants in the study will be randomly assigned to receive either Remibrutinib or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for 68 weeks, during which the participants’ response to the treatment will be closely monitored. The main goal is to see if Remibrutinib can reduce the number of abscesses and inflammatory nodules by at least 50% after 16 weeks of treatment.

In addition to Remibrutinib, the study will also involve the use of other treatments like Triamcinolone Acetonide and Salicylic Acid, which are known for their anti-inflammatory properties, as well as systemic antibiotics like Clindamycin Hydrochloride. These treatments will be used to support the main study medication and help manage the symptoms of Hidradenitis Suppurativa. The study aims to provide valuable information on the potential benefits of Remibrutinib for individuals suffering from this challenging condition.